Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EpiSign International: Health System Impact Assessment and Expanding Clinical Utilization of Epi/Genomic Testing in Rare Diseases and Beyond

NCT07839754 is registered in ClinicalTrials.gov with University of Manchester as lead sponsor.

NCT NCT07839754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07839754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EpiSign International: Health System Impact Assessment and Expanding Clinical Utilization of Epi/Genomic Testing in Rare Diseases and Beyond
Lead sponsor
University of Manchester
Phase
Observational
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2029
Enrollment
192 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congenital abnormalities, genetic diseases, inborn, rare disease, undiagnosed disease